Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/46166
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- INI - Artigos de Periódicos [3460]
Metadatos
Mostrar el registro completo del ítem
COHORT PROFILE: STUDY ON ZIKA VIRUS INFECTION IN BRAZIL (ZIKABRA STUDY)
Autor
Calvet, Guilherme Amaral
Kara, Edna Oliveira
Landoulsi, Sihem
Habib, Ndema
Bôtto-Menezes, Camila Helena Aguiar
Franca, Rafael Freitas de Oliveira
Neto, Armando Menezes
Castilho, Marcia da Costa
Fernandes, Tatiana Jorge
Pereira, Gerson Fernando
Giozza, Silvana Pereira
Bermúdez, Ximena Pamela Díaz
Modjarrad, Kayvon
Lima, Noemia
Brasil, Patrícia
Lacerda, Marcus Vinicius Guimarães de
Filippis, Ana Maria Bispo de
Broutet, Nathalie Jeanne Nicole
ZIKABRA Study Team
Kara, Edna Oliveira
Landoulsi, Sihem
Habib, Ndema
Bôtto-Menezes, Camila Helena Aguiar
Franca, Rafael Freitas de Oliveira
Neto, Armando Menezes
Castilho, Marcia da Costa
Fernandes, Tatiana Jorge
Pereira, Gerson Fernando
Giozza, Silvana Pereira
Bermúdez, Ximena Pamela Díaz
Modjarrad, Kayvon
Lima, Noemia
Brasil, Patrícia
Lacerda, Marcus Vinicius Guimarães de
Filippis, Ana Maria Bispo de
Broutet, Nathalie Jeanne Nicole
ZIKABRA Study Team
Afiliación
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil / Amazonas State University (UEA). School of Health Sciences. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brasil.
Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Ministry of Health. Health Surveillance Secretariat. Department of Chronic Condition Diseases and Sexually Transmitted Infections. Brasilia, DF, Brazil.
Ministry of Health. Health Surveillance Secretariat. Department of Chronic Condition Diseases and Sexually Transmitted Infections. Brasilia, DF, Brazil.
University of Brasilia. Department of Public Health. Brasília, DF, Brazil.
Walter Reed Army Institute of Research. Emerging Infectious Diseases Branch. Silver Spring, MD, United States of America.
Walter Reed Army Institute of Research. Emerging Infectious Diseases Branch. Silver Spring, MD, United States of America.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Leônidas & Maria Deane. Manaus, AM, Brasil / Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil / Amazonas State University (UEA). School of Health Sciences. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil / Amazonas State University (UEA). School of Health Sciences. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Departamento de Virologia e Terapia Experimental. Recife, PE, Brasil.
Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Ministry of Health. Health Surveillance Secretariat. Department of Chronic Condition Diseases and Sexually Transmitted Infections. Brasilia, DF, Brazil.
Ministry of Health. Health Surveillance Secretariat. Department of Chronic Condition Diseases and Sexually Transmitted Infections. Brasilia, DF, Brazil.
University of Brasilia. Department of Public Health. Brasília, DF, Brazil.
Walter Reed Army Institute of Research. Emerging Infectious Diseases Branch. Silver Spring, MD, United States of America.
Walter Reed Army Institute of Research. Emerging Infectious Diseases Branch. Silver Spring, MD, United States of America.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de doenças febris agudas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Leônidas & Maria Deane. Manaus, AM, Brasil / Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD). Department of Malaria. Manaus, AM, Brazil / Amazonas State University (UEA). School of Health Sciences. Manaus, AM, Brazil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Flavivírus. Rio de Janeiro, RJ, Brasil.
World Health Organization. Department of Sexual and Reproductive Health and Research. Geneva, Switzerland.
Resumen en ingles
Zika virus (ZIKV) has been detected in blood, urine, semen, cerebral spinal fluid, saliva, amniotic fluid, and breast milk. In most ZIKV infected individuals, the virus is detected in the blood to one week after the onset of symptoms and has been found to persist longer in urine and semen. To better understand virus dynamics, a prospective cohort study was conducted in Brazil to assess the presence and duration of ZIKV and related markers (viral RNA, antibodies, T cell response, and innate immunity) in blood, semen, saliva, urine, vaginal secretions/menstrual blood, rectal swab and sweat. The objective of the current manuscript is to describe the cohort, including an overview of the collected data and a description of the baseline characteristics of the participants. Men and women ≥ 18 years with acute illness and their symptomatic and asymptomatic household contacts with positive reverse transcriptase-polymerase chain reaction test for ZIKV in blood and/or urine were included. All participants were followed up for 12 months. From July 2017 to June 2019, a total of 786 participants (284 men, 502 women) were screened. Of these, 260 (33.1%) were enrolled in the study; index cases: 64 men (24.6%), 162 (62.3%) women; household contacts: 12 men (4.6%), 22 (8.5%) women. There was a statistically significant difference in age and sex between enrolled and not enrolled participants (p<0.005). Baseline sociodemographic and medical data were collected at enrollment from all participants. The median and interquartile range (IQR) age was 35 (IQR; 25.3, 43) for men and 36.5 years (IQR; 28, 47) for women. Following rash, which was one of the inclusion criteria for index cases, the most reported symptoms in the enrollment visit since the onset of the disease were fever, itching, arthralgia with or without edema, non-purulent conjunctivitis, headache, and myalgia. Ten hospitalizations were reported by eight patients (two patients were hospitalized twice) during follow up, after a median of 108 days following symptom onset (range 7 to 266 days) and with a median of 1.5 days (range 1 to 20 days) of hospital stay. A total of 4,137 visits were performed, 223 (85.8%) participants have attended all visits and 37 (14.2%) patients were discontinued.
Compartir